Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 16/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7055144 | 0.95 | ENPEP (0.40) | ENPEPS1PR2S1PR1S1PR3TP53 | |
| SCHEMBL2167503 | 0.89 | ENPEP (0.42) | ENPEPS1PR2S1PR1S1PR3TP53 | |
| SCHEMBL2167950 | 0.89 | ENPEP (0.42) | ENPEPS1PR2S1PR1S1PR3TP53 | |
| SCHEMBL2167506 | 0.89 | ENPEP (0.42) | ENPEPS1PR2S1PR1S1PR3TP53 | |
| SCHEMBL2168652 | 0.82 | ENPEP (0.43) | ENPEPS1PR2S1PR1S1PR3TP53 | |
| SCHEMBL2168649 | 0.82 | ENPEP (0.43) | ENPEPS1PR2S1PR1S1PR3TP53 | |
| SCHEMBL2167512 | 0.82 | ENPEP (0.43) | ENPEPS1PR2S1PR1S1PR3TP53 | |
| SCHEMBL7621164 | 0.80 | S1PR2 (0.45) | ENPEPS1PR2S1PR1S1PR3TP53 | |
| SCHEMBL3626027 | 0.76 | ENPEP (0.43) | ENPEPS1PR2S1PR1S1PR3TP53 | |
| SCHEMBL27651670 | 0.75 | S1PR2 (0.44) | ENPEPS1PR2S1PR1S1PR3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4726304-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| JP-2003517458-A | — | — | 2003-05-27 | — | — | JP | claimed |
| EP-1276483-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-01-22 | — | — | EP | claimed |
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (GI) | 2002-08-22 | — | — | US | claimed |
| WO-2000064420-A2 | COMPOSITIONS AND METHODS FOR TREATING AMYLOIDOSIS USING SULPHONATE DERIVATIVES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-11-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115717-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | ENPEP 63/4885S1PR2 1184/4885S1PR1 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.